The study, presented at the American Society of Hematology meeting, also suggested that a moleculary guided strategy may lead to better outcomes than standard of care.
Amgen's latest deal with a pharma company will see its clonoSeq assay used for minimal residual disease testing in a clinical trial for venetoclax.
An analysis found a 14 percent prevalence of germline cancer risk mutations and a 57 percent prevalence of variants of unknown significance.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
PBS NewsHour reports on initiatives that aim to bolster the representation of minority groups in research.
Novartis has paused a trial of its Zolgensma gene therapy that treats spinal muscular atrophy, the Wall Street Journal reports.
NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.
Direct-to-consumer genetic testing company 23andMe is partnering with clinical trial firm TrialSpark to address low recruitment into clinical trials.
The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma.
The Guardian writes that UK researchers are concerned that a no-deal Brexit would affect their ability to collaborate on cancer trials in the European Union.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.